Wound Biologics SOP Template: Evaluation-to-Formulary

Wound Biologics SOP Template: Evaluation-to-Formulary Workflow for Wound Centers

This template gives wound centers a structured, adaptable standard operating procedure for moving a biologic graft product from initial evaluation through trial use, formulary vote, staff training, and post-adoption outcomes tracking. It assumes a functioning value analysis committee (VAC) and bridges the decision frameworks in our buyer's guide and evaluation checklist into an operational workflow. It is not a purchasing recommendation and does not replace institutional procurement policies or compliance review.

Why a Written SOP Matters for Biologics

Most supply items can be added to formulary on unit price and contract terms alone. A biologic graft cannot. It carries regulatory classification questions under FDA's human cells, tissues, and cellular and tissue-based products (HCT/P) framework (21 CFR Part 1271), storage and handling obligations that vary by processing format, coding requirements in the HCPCS Q-code series, and documentation expectations that feed both reimbursement claims and quality metrics. Under the CY 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F), skin substitutes are paid at a flat national rate of $127.14 per square centimeter, which means the margin for coding errors or documentation gaps is thinner than it was under the former ASP-plus-6% model.

A written SOP does three things an email thread cannot:

- It creates an audit trail. Every evaluation, vote, training, and outcomes review is dated and owned. If a payer or an accreditor asks why a product is on formulary, the answer is a binder, not a memory. - It prevents workflow drift. Biologics fail in practice more often than they fail in committee. The SOP forces the training and competency check that most centers intend to do and some actually do. - It links procurement to quality. The same documentation that justifies formulary addition also feeds healing-rate tracking, Joint Commission performance measures, and payer audit responses.

Step 1 — Trigger and Product Intake

Every evaluation starts with a documented request. The requester — a clinician, a materials manager, or a supplier representative — completes a one-page intake form and submits it to the VAC coordinator. The intake form captures:

- Product name, manufacturer, and processing format (dehydrated, cryopreserved, micronized, or other) - Requested indication and target wound types - Requester's clinical rationale (one paragraph, minimum) - Supplier contact and evidence file submitted (yes/no)

The VAC coordinator logs the request, assigns an evaluation number, and schedules the product for the next committee review cycle. No product proceeds to evaluation without a complete intake form. This single rule eliminates most unforced errors: products that arrive through the loading dock instead of the committee rarely have their paperwork in order.

Step 2 — Regulatory and Infrastructure Screening

Before clinical review begins, the VAC coordinator verifies two gates that disqualify most candidates before the committee spends clinical time on them.

A product that clears both gates proceeds to full evaluation. One that fails either gate is documented and archived.

Step 3 — Evidence Review and VAC Scoring

The clinical lead assembles an evidence file using the structured domains from our evaluation checklist. The minimum domains are:

1. Clinical evidence quality. RCTs, systematic reviews, and meta-analyses in the target wound type, with PMID-level citation detail. A systematic review and meta-analysis in the Journal of Foot and Ankle Research (PMID 36104736, 2022) evaluated human amniotic membrane products in diabetic foot ulcers and reported significantly higher complete closure rates versus standard care. Evidence is product-specific; a published RCT for one manufacturer's product does not validate a competitor's product in the same category. 2. Indication match. Whether the published evidence covers the wound types and severity levels the center actually treats. 3. Coding and coverage. The assigned HCPCS Q-code, Medicare coverage under the $127.14/cm² flat rate, and commercial payer requirements. Cross-reference our HCPCS coding reference for the current code set. 4. Total cost of adoption. Unit price plus freezer costs, training time, waste from expired inventory, and staff time per application. Cost-per-closure modeling — not unit price — is the correct denominator. See our ROI framework for a worked model. 5. Vendor credentialing. AATB accreditation status, quality management system documentation, and adverse event reporting obligations.

The VAC scores each domain on a defined scale (e.g., 1–5 with written justification) and votes. The vote outcomes are documented: approve, approve with conditions (e.g., restricted to specific wound types or a defined trial cohort), defer pending additional evidence, or reject. Conditions are written into the SOP record, not left as verbal understandings.

Step 4 — Trial Protocol

Approved products move to a defined trial period before unrestricted formulary status. The trial protocol specifies:

- Cohort size and selection criteria. E.g., 15–25 consecutive patients meeting defined wound type, size, and standard-of-care failure criteria. - Application protocol. Standardized wound bed preparation, application technique, and dressing regimen, consistent with current guidelines and the manufacturer's instructions for use. - Endpoints. Percent wound area reduction at 4 weeks, complete closure rate at 12 weeks, number of applications to closure, and adverse events. The percent wound area reduction benchmark over the first 4 weeks of care is a validated predictor of 12-week closure in diabetic foot ulcer studies (PMID 26978860, Snyder et al., Wounds 2016). - Review date. A calendar date, set at trial initiation, when the committee reconvenes to review results. Not "when we have enough data." A date.

The clinical lead is responsible for ensuring trial data is captured in structured fields — wound dimensions by a single named method, dated assessments, and application records that link to the clinical note. Free-text documentation cannot be trended or audited, and untrendable data is not evidence.

Step 5 — Formulary Decision

The VAC reconvenes on the review date and evaluates the trial cohort against the pre-specified endpoints. Three outcomes:

- Full formulary addition. The product is added to formulary for the approved indications with unrestricted use. - Conditional formulary addition. The product remains on formulary for a defined subset (e.g., specific wound types or severity tiers) with a re-review date. - Removal. The product is removed from trial status and the evaluation file is archived. The removal reason is documented for future reference.

The formulary decision is recorded in the SOP log with the vote count, dissenting opinions, and conditions. This record is the document a CFO, a payer, or an accreditor will ask for.

Step 6 — Staff Training and Competency Verification

Formulary status triggers a training requirement. The SOP specifies:

- Trainer. A named individual — either a manufacturer's clinical specialist or an internal wound care clinician who has completed the manufacturer's training-of-trainers program. - Training date. Scheduled before the first non-trial application. - Competency check. A documented skills verification for each clinician who will apply the product. This can be observed application, case review, or a written assessment, depending on the product's complexity. - Training records. Retained in the staff education file and available for survey review.

An unapplied graft is an expensive shelf decoration. The training step is where most biologics programs actually succeed or fail, and it is the step most often skipped because everyone assumes someone else handled it.

Step 7 — Post-Adoption Outcomes Tracking

Formulary addition is not the end of the SOP. The quality officer owns an ongoing outcomes file that tracks:

- Healing rate. Percent of treated wounds achieving complete closure at 12 weeks, stratified by wound type. - Time to closure. Mean weeks to complete closure by wound type. - Applications to closure. Mean number of applications per healed wound. - Adverse events. Product-related complications, infections, and graft failures. - Utilization. Monthly application volume, payer mix, and denial rate on biologic claims.

These metrics feed three downstream obligations: quarterly VAC re-review (for conditionally approved products), Joint Commission quality reporting under the program's defined measures (see our tracking guide), and payer audit response. The same wound assessment data that clinicians document at the bedside is the data that answers all three.

The quality officer presents a summary report to the VAC at a defined interval — quarterly for the first year, semi-annually thereafter — with a standing agenda item for products showing adverse trends: rising denial rates, declining healing rates versus the trial cohort, or utilization that diverges from the approved indication.

One-Page Template Skeleton

The following skeleton can be adapted to your institution's document format. Bracketed sections should be populated with institution-specific values.

---

- Requester completes intake form: product name, manufacturer, format, requested indication, clinical rationale. - VAC coordinator logs request and assigns evaluation number.

- Gate A: Regulatory classification verified in writing (361 HCT/P vs 351 biologic). - Gate B: Storage and handling requirements mapped against facility capability. - Both gates must be documented before proceeding.

- Clinical lead assembles evidence file: evidence quality (PMID-level), indication match, coding/coverage, total cost of adoption, vendor credentialing. - VAC scores domains and votes: approve / approve with conditions / defer / reject. - Vote record filed in SOP log.

- Cohort size: [___] patients. Selection criteria: [___]. - Endpoints: % area reduction at 4 weeks, closure rate at 12 weeks, applications to closure, adverse events. - Review date: [___].

- Full addition / conditional addition / removal, based on trial results against pre-specified endpoints.

- Trainer: [___]. Training date: [___]. - Competency verification completed for all applying clinicians.

- Metrics: healing rate at 12 weeks, time to closure, applications to closure, adverse events, utilization, denial rate. - Quality officer presents summary to VAC quarterly (year 1) / semi-annually (ongoing). - Standing re-review trigger: denial rate above [___]%, healing rate below [___]%, or utilization outside approved indication.

---

Where This SOP Fits in the Workflow

This template operationalizes the decision frameworks in the existing cluster. The buyer's guide covers the six questions a VAC should ask before approving any graft product. The evaluation checklist provides the domain-level detail for Step 3. The VAC ROI guide provides the cost-per-closure model for the financial domain. The HCPCS reference is the coding cross-check. This SOP is the connective tissue that turns those documents into a repeatable institutional process.

Related Resources

- Wound Biologics Buyer's Guide — decision criteria for graft evaluation - Wound Center Biologics Evaluation Checklist — domain-level evaluation detail for Step 3 - Wound Biologics ROI for VACs — cost-per-closure modeling framework - Wound Biologics HCPCS Coding & Billing Reference — Q-code cross-reference for coding verification - Joint Commission Wound Care Measures Tracking Guide — quality data workflow for Step 7

---

Internal Link Targets (post-publish)

- `/blog/wound-biologics-buyers-guide-procurement-decision-matrix` — W38 P0, primary decision-framework sibling - `/blog/wound-center-biologics-evaluation-checklist` — July P1, Step 3 evidence file source - `/blog/wound-center-product-evaluation-value-analysis-committee-guide` — July P1, six-domain VAC framework - `/blog/wound-care-biologics-roi-value-analysis-committee` — W25 P0, cost-per-closure model - `/blog/wound-biologics-hcpcs-coding-billing-reference` — Aug P1, Q-code cross-check - `/blog/joint-commission-wound-care-performance-measures-tracking-guide` — Sept P1, outcomes data workflow sibling